Nissinen R, Paimela L, Julkunen H, Tienari P J, Leirisalo-Repo M, Palosuo T, Vaarala O
National Public Health Institute, Department of Molecular Medicine, Biomedicum, Helsinki, Finland.
Scand J Rheumatol. 2003;32(6):337-42. doi: 10.1080/03009740410004990.
Antibodies to citrulline-containing epitopes of filaggrin are highly specific for rheumatoid arthritis (RA). We studied whether the enzyme peptidylarginine deiminase (PAD), responsible for the post-translational modification of peptide-bound arginine residues to citrulline, constitutes an antigen for patients with RA.
IgG antibodies to PAD were measured by enzyme-linked immunosorbent assay (ELISA) in sera from patients with RA, systemic lupus erythematosus (SLE), primary Sjögren syndrome (pSS), multiple sclerosis (MS) and healthy controls.
Compared to healthy controls, raised levels of IgG antibodies to PAD were found in 50 of 57 recent-onset RA patients (88%) and in 40 (70%) of the same 57 patients 3 years later (p<0.0001 for both comparisons). Eleven of 51 (22%) patients with RA of long duration, 19/43 (44%) patients with SLE and 16/19 (84%) patients with pSS, but none of 20 patients with MS, had elevated anti-PAD levels.
The arginine-citrulline converting enzyme PAD was recognized as a new antigen against which patients with inflammatory rheumatic diseases frequently show IgG class antibodies.
针对丝聚蛋白含瓜氨酸表位的抗体对类风湿关节炎（RA）具有高度特异性。我们研究了负责将肽结合的精氨酸残基翻译后修饰为瓜氨酸的酶——肽基精氨酸脱亚氨酶（PAD）是否构成RA患者的一种抗原。
采用酶联免疫吸附测定（ELISA）法检测RA患者、系统性红斑狼疮（SLE）患者、原发性干燥综合征（pSS）患者、多发性硬化症（MS）患者及健康对照者血清中抗PAD的IgG抗体。
与健康对照相比，57例近期发病的RA患者中有50例（88%）抗PAD的IgG抗体水平升高，3年后这57例患者中有40例（70%）抗体水平升高（两次比较p均<0.0-01）。51例病程较长的RA患者中有11例（22%）、43例SLE患者中有19例（44%）、19例pSS患者中有16例（84%）抗PAD水平升高，但20例MS患者中无一例升高。
精氨酸-瓜氨酸转化酶PAD被认为是一种新抗原，炎症性风湿疾病患者常出现针对该抗原的IgG类抗体。
